Oncolytic viruses: past and present
European Pharmaceutical Review
AUGUST 25, 2022
IN 2022, treating glioblastoma (GBM) remains an uphill battle. This strategy has failed to gain a foothold in the past as the patient’s immune system interferes, destroying the unprotected oncolytic viruses. The remaining missing piece of the puzzle has been how to shield them from destruction by the immune system.
Let's personalize your content